Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$2.805M
Current Assets
2025 Q2
Current Liabilities
2025 Q2
Current Ratio
2025 Q2
1160.08%
Total Assets
2025 Q2
Total Liabilities
2025 Q2
Book Value
2025 Q2
$2.788M
Cash
2025 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $6.13 Million

About TITAN PHARMACEUTICALS INC

Titan Pharmaceuticals Inc is a US-based company operating in IT Services industry. The company is headquartered in New York City, New York. Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Industry: Biological Products, (No Diagnostic Substances) Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. Avenir Wellness Solutions, Inc. Eloxx Pharmaceuticals Inc Evofem Biosciences Inc Johnson & Johnson KALA BIO Inc MJ Holdings, Inc. OTONOMY, INC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support